|
Security
Type
|
Security
Class
Title
|
Fee
Calculation
or Carry
Forward
Rule
|
Amount
Registered(1)
|
Proposed
Maximum
Offering
Price
Per
Security
|
Maximum
Aggregate
Offering
Price
|
Fee Rate
|
Amount of
Registration
Fee
|
Newly Registered Securities
|
||||||||
Fees to Be Paid
|
Equity
|
Ordinary Shares, par value NIS 0.20 per share
|
Other (Rule 457(c))
|
3,384,616(2)
|
$2.865(3)
|
$9,696,924.84
|
.0001476
|
$1,431.27
|
Fees Previously Paid
|
—
|
—
|
—
|
—
|
—
|
—
|
|
—
|
|
Total Offering Amounts
|
|
$9,696,924.84
|
|
$1,431.27
|
|||
|
Total Fees Previously Paid
|
|
|
|
—
|
|||
|
Total Fee Offsets
|
|
|
|
—
|
|||
|
Net Fee Due
|
|
|
|
$1,431.27
|
(1)
|
The ordinary shares, par value NIS 0.20 per share (“ordinary shares”) of Evogene Ltd. (“Evogene” or the “Company”) being registered hereunder are being registered for sale by the selling shareholder named in the prospectus. In accordance with Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), the Registration Statement for which this filing fee table serves as an exhibit also covers an indeterminate number of additional ordinary shares as may be issuable as a result of share splits, share
dividends or similar transactions.
|
(2)
|
Consists of 3,384,616 ordinary shares underlying ordinary warrants (the “ordinary warrants”), consisting of 1,692,308 ordinary shares underlying Series A ordinary warrants
and 1,692,308 ordinary shares underlying Series B ordinary warrants, which were sold by the Company to the selling shareholder pursuant to a Securities Purchase Agreement, dated as of August 23, 2024, by and between the Company and the
selling shareholder.
|
(3)
|
Estimated solely for purpose of calculating the amount of the registration fee pursuant to Rule 457(c) under the Securities Act based on the average of the high ($3.01) and low ($2.72) sales prices of the
ordinary shares on the Nasdaq Capital Market on September 16, 2024.
|